NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

$259.94

-9.10 (-3.38%)

(As of 06/2/2023 ET)

Compare

Today's Range: $255.41
▼
$271.65
50-Day Range: $234.08
▼
$312.00
52-Week Range: $57.21
▼
$322.67

Volume: 477,100 shs
Average Volume: 386,559 shs
Market Capitalization: $4.75 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $312.36

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 20.2% Upside
$312.36 Price Target
Short Interest: Healthy
9.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: 0.39
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($18.65) to ($8.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

267th out of 983 stocks

Pharmaceutical Preparations Industry

120th out of 486 stocks

2.4

Analyst's Opinion

Consensus Rating
Madrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $312.36, Madrigal Pharmaceuticals has a forecasted upside of 20.2% from its current price of $259.94.
Amount of Analyst Coverage
Madrigal Pharmaceuticals has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
9.01% of the float of Madrigal Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Madrigal Pharmaceuticals has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Madrigal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Madrigal Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Madrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Madrigal Pharmaceuticals is -0.92.

2.4

News and Social Media Coverage

News Sentiment
Madrigal Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Madrigal Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 7 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
8 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.71% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.98% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($18.65) to ($8.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Madrigal Pharmaceuticals is -14.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Madrigal Pharmaceuticals is -14.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Madrigal Pharmaceuticals has a P/B Ratio of 31.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

May 30, 2023 | seekingalpha.com

Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)

May 29, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to "Hold" at StockNews.com

June 3, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.

May 26, 2023 | fool.com

Madrigal Pharmaceuticals (NASDAQ: MDGL)

May 25, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 4.1% Higher

May 23, 2023 | benzinga.com

Looking At Madrigal Pharmaceuticals's Recent Unusual Options Activity

May 22, 2023 | americanbankingnews.com

StockNews.com Downgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) to Sell

May 21, 2023 | americanbankingnews.com

Brokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Target Price at $312.36

June 3, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

May 18, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Short Interest Down 6.8% in April

May 17, 2023 | msn.com

Unusual Call Option Trade in Madrigal Pharmaceuticals (MDGL) Worth $2,637.87K

May 16, 2023 | msn.com

Oppenheimer Maintains Madrigal Pharmaceuticals (MDGL) Outperform Recommendation

May 16, 2023 | msn.com

Analyst Expectations for Madrigal Pharmaceuticals's Future

May 16, 2023 | finance.yahoo.com

Why These 3 Nasdaq Stocks Buckled Today

May 16, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) PT Raised to $350.00 at Oppenheimer

May 15, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Raised to Hold at StockNews.com

May 11, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

May 11, 2023 | finance.yahoo.com

Top Small-Cap Stocks for May 2023

May 11, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 11.4%

May 10, 2023 | msn.com

Canaccord Genuity Reiterates Madrigal Pharmaceuticals (MDGL) Buy Recommendation

May 9, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

May 9, 2023 | finance.yahoo.com

Why Madrigal Pharmaceuticals Stock Is Slumping Today

May 9, 2023 | finanznachrichten.de

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

May 9, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

May 8, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

May 8, 2023 | americanbankingnews.com

Reviewing Biohaven (NYSE:BHVN) and Madrigal Pharmaceuticals (NASDAQ:MDGL)

May 3, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week High at $321.00

See More Headlines

MDGL Price History

30 days | 90 days | 365 days | Advanced Chart

MDGL Company Calendar

Last Earnings: 5/09/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MDGL
CUSIP: 87162T20
CIK: 1157601
Web: www.madrigalpharma.com
Phone: (267) 824-2827
Fax: 781-274-8228
Employees: 71
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $312.36
High Stock Price Forecast: $390.00
Low Stock Price Forecast: $194.00
Forecasted Upside/Downside: +20.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($18.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-295,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -285.00%
Return on Assets: -117.65%

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 3.37
Quick Ratio: 3.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.21 per share
Price / Book: 31.66

Miscellaneous

Outstanding Shares: 18,290,000
Free Float: 12,855,000
Market Cap: $4.75 billion
Optionable: Optionable
Beta: -0.70

Social Links

Key Executives

Paul A. Friedman
Chairman, President & Chief Executive Officer

Alex G. Howarth
Chief Financial Officer

Edward Chiang
SVP-Clinical & Technical Operations

Rebecca A. Taub
Director & Chief Medical Officer

Stephen Dodge
Senior Vice President-Global Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.
What is Madrigal Pharmaceuticals' stock price forecast for 2023?: 10 brokers have issued 12-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $194.00 to $390.00. On average, they expect the company's stock price to reach $312.36 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.
How have MDGL shares performed in 2023?: Madrigal Pharmaceuticals' stock was trading at $290.25 at the beginning of the year. Since then, MDGL stock has decreased by 10.4% and is now trading at $259.94.
View the best growth stocks for 2023 here.
When is Madrigal Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MDGL earnings forecast.
How were Madrigal Pharmaceuticals' earnings last quarter?: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($4.23) earnings per share for the quarter, beating the consensus estimate of ($4.78) by $0.55.
What ETFs hold Madrigal Pharmaceuticals' stock?: ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Alger Mid Cap 40 ETF (FRTY), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Pharmaceuticals ETF (IHE), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Madrigal Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).
What is Madrigal Pharmaceuticals' stock symbol?: Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
Who are Madrigal Pharmaceuticals' major shareholders?: Madrigal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (9.11%), BlackRock Inc. (5.21%), Perceptive Advisors LLC (3.56%), State Street Corp (2.84%), Assenagon Asset Management S.A. (2.85%) and FMR LLC (1.44%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy.
View institutional ownership trends.
How do I buy shares of Madrigal Pharmaceuticals?: Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Madrigal Pharmaceuticals' stock price today?: One share of MDGL stock can currently be purchased for approximately $259.94.
How much money does Madrigal Pharmaceuticals make?: Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.75 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.10) on an earnings per share basis.
How can I contact Madrigal Pharmaceuticals?: Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial